This paper presents the first report of the use of topical azathioprine in the management of persistent symptomatic chronic oral graft-versus-host disease (GVHD). Topical azathioprine suspension was used as an oral rinse and was swallowed, maintaining the previously prescribed systemic dose of azathioprine, and resulted in improvement in a case of oral GVHD that was resistant to other approaches to management. Topical azathioprine may provide additional therapy in the management of immune-mediated oral mucosal disease. Clinical trials appear warranted based upon the results of topical azathioprine use as presented in this case report. Bone Marrow Transplantation (2000) 25, 683-687. Keywords: oral graft-versus-host disease; bone marrow transplant; azathioprine Bone marrow transplant (BMT) is a common treatment for many hematologic malignancies and immune deficiency states, and is used with increasing frequency for salvage therapy of many solid malignancies. Oral involvement with graft-versus-host disease (GVHD) may occur in 25-70% of patients, 1 despite GVHD prophylaxis. The oral findings of acute GVHD include painful desquamative, erythematous, and ulcerative mucosal lesions.
Bone marrow transplant (BMT) is a common treatment for many hematologic malignancies and immune deficiency states, and is used with increasing frequency for salvage therapy of many solid malignancies. Oral involvement with graft-versus-host disease (GVHD) may occur in 25-70% of patients, 1 despite GVHD prophylaxis. The oral findings of acute GVHD include painful desquamative, erythematous, and ulcerative mucosal lesions. 1, 2 Chronic oral GVHD can display lichenoid, erythematous, and ulcerative lesions, manifestations of systemic sclerosis and a sicca syndrome consisting of xerostomia and salivary gland atrophy. [1] [2] [3] Oral complications include pain due to the mucosal changes and altered or reduced taste, and may potentially have an impact on speech, deglutition, and use of oral prostheses. Oral infection, particularly due to candida species, and dental demineralization and caries may also occur.
The management of chronic oral GVHD consists of appropriate systemic therapy combined with proper oral hygiene and use of topical steroids. 1, 2 In addition, immunosuppressants such as cyclosporin A 4, 5 have been used as topical therapy in chronic oral GVHD. If the dry mouth cannot be effectively managed, the complications of persisting xerostomia, including candidosis and caries risk, must require treatment.
We report a severe case of chronic oral GVHD refractory to systemic and topical therapies, which was managed successfully with the addition of a topically applied liquid formulation of the immunosuppressive drug azathioprine (AZA).
Case report
A 34-year-old male presented with pancytopenia in late October 1994, and was diagnosed with aplastic anemia. He received a matched sibling donor bone marrow transplant on 1 November 1994, and was seen monthly following transplant. He had continuing difficulties with GVHD, including oral involvement. This case report focuses on the progress of the oral complications. His oral status was evaluated at day 100 post BMT in March 1995. Oral findings were consistent with pseudomembranous candidiasis, and ulceration on the left cheek was consistent with minor trauma. There were no clinical findings suggestive of oral GVHD, and saliva volumes were not decreased. Acute (grade II) GVHD (skin and liver) was treated with systemic corticosteroids. Therapy with systemic cyclosporin (3 mg/kg twice a day) and prednisone (1 mg/kg/day) was commenced in May 1995.
Persisting oral problems developed, including recurrent infections (herpes simplex virus and candida) and ulcerations secondary to GVHD, and had a major negative impact on the post-BMT course. Leukoplakia developed involving the lateral borders of the tongue. In May 1995, he reported several days of sore mouth involving the cheeks and gums. Oral changes included findings consistent with GVHD and reactivation of HSV. HSV and candida were confirmed on culture. The clinical findings consistent with HSV improved with the prescription of acyclovir. However, findings of oral GVHD persisted despite continuing systemic immunosuppressive therapy, with lichenoid changes associated with moderate erythema on the nonkeratinized mucosa of the cheeks, tongue and lips. Multiple dilated salivary ducts were visualized on the soft palate. Ulcerations of 3-4 mm in diameter were present on the lateral borders, the dorsum, and the tip of the tongue. Due to findings of increasing GVHD and possible candidosis, a biopsy of the lip mucosa and minor salivary glands was completed, which demonstrated changes consistent with GVHD. Biopsy of the ulcer on the cheek was consistent with HSV.
GVHD was difficult to control despite many modifications in both systemic and topical immunosuppression. Topical corticosteroids including dexamethasone rinse (0.4 mg/ml), fluocinonide gel, and dermovate cream were ineffective. Topical cyclosporin preparations were ineffective (rinse) or poorly tolerated (gel). Benefit was noted with administration of high-dose systemic steroids, although this was associated with undesirable side-effects (hypertension, myopathy, weight gain and candidosis). Intravenous immunoglobulin was added in April 1996 because of systemic hypogammaglobulinemia. Following development of an esophageal stricture (November 1996), tacrolimus (FK506) was begun along with AZA tablets (100 mg/day), and cyclosporin A was discontinued. Prednisone dose was maintained relatively constant after November 1996 (10 mg/day). On October 24 1997, increasing oral sensitivity associated with oral GVHD was reported. Extensive lichenoid striae with moderate erythema and ulceration involving the lateral tongue on the right and left and the right cheek was seen. A second oral biopsy of lip mucosa and minor salivary glands was completed, which was interpreted as grade II GVHD. Hydroxychloroquine was added (400 mg/day) in November 1997, but was discontinued in December 1997, due to diarrhea.
In December 1997, AZA was given as a suspension (25 mg four times a day (rinse 1-2 min then swallow)), to maintain the systemic dose of 100 mg/day. The AZA suspension was made by combining AZA powder with a cherry flavored methylcellulose (1%) suspending vehicle (5 mg/ml). The oral findings present prior to prescription of AZA suspension are shown in Figure 1 . There was clinical evidence of improvement in both oral ulceration and erythema and oral sensitivity with the use of the AZA suspension ( Figure 2 ). Lichenoid changes were decreased, and a single ulcer measuring 5 × 22 mm remained on the left tongue. The ulcer had thickened, rolled borders, although its central area appeared to be partially re-epithelialized.
In early March 1998, the patient stopped the AZA rinse, returning to the same dose by tablet, and within 10 days increased mouth discomfort was reported. Examination revealed an ulcer on the left tongue (a 20 × 4 mm penetrating ulcer with 1 mm red borders, and a more anterior 5 × 6 mm ulcer) and a new 3 mm erosion on the right tongue with minimal erythema.
In April 1998, topical AZA rinse was resumed (25 mg/ml, 5 ml three times a day) and he reported reduced oral sensitivity limited to the left lateral border of the tongue, which corresponded to a 5 × 15 mm superficial ulcer, with non-thickened, non-indurated margins. Patchy atrophy of the dorsal tongue and mild lichenoid changes without erythema at sites of prior mucosal ulceration were present. Early in May he reported reduced oral sensitivity, and clinical examination revealed atrophic mucosa of the dorsal tongue and erythema of the lateral tongue, with resolution of the ulceration and mild erythema present on the cheeks.
In May he was admitted to hospital for pneumonia and was treated with i.v. antibiotics. At that time, AZA suspension was replaced with AZA tablets (continuing dose of 25 mg three times a day), and prednisone was increased to 20 mg/day. Examination revealed minimal erythema and lichenoid striations in the cheeks and gingiva, a 15 × 4 mm ulceration was present on the left lateral tongue, with clinically increased thickness of the border of the ulceration. Resumption of AZA suspension and continuing systemic treatment was recommended. The oral ulcers were virtually resolved at the last follow-up visit, following resumption of AZA suspension (Figure 3) .
Discussion
Azathioprine is a purine analog that is quickly metabolized in vivo into 6-mercaptopurine (6MP). These agents act as Bone Marrow Transplantation purine antagonists, which interfere with the synthesis of DNA, RNA and protein. 6 They are known to act as immunomodulators due to selective effects on T cells and T celldependent responses, 7 as well as effecting natural killer cell activity 8 and humoral responsiveness. 9 Systemic azathioprine has proven effective as a steroid-sparing immunosuppressant in the management of other chronic oral vesiculoerosive diseases such as pemphigus vulgaris and lichen planus. [10] [11] [12] The side-effects of systemic therapy with azathioprine can be categorized as either allergic or nonallergic in nature. The allergic-type reactions appear to be dose-independent and can include rash, fever, pancreatitis, arthralgias, malaise, nausea and diarrhea. The non-allergic effects are thought to be dose-dependent, and include leukopenia, thrombocytopenia, hepatitis, infection and malignancy. In light of these significant adverse effects, dosing and toxicity monitoring, including a complete blood count and liver enzyme studies, should be performed throughout the course of the patient's therapy.
Azathioprine has been shown to be stable as a compounded liquid. 13 There exist only sporadic reports of the use of topical AZA in oral diseases such as aphthous stomatitis and periodontosis 14, 15 and as immunosuppressive therapy in the prevention of corneal graft rejection. 16, 17 The role of systemic AZA in the management and prevention of inflammatory bowel disease (IBD) has been well characterized, 18, 19 and shows AZA to be efficacious in the long- term management of inflammatory bowel diseases such as Crohn's disease, with less long-term toxicity than that associated with corticosteroids. 20 Recent studies of the pharmacokinetics of alternative formulations of azathioprine in the treatment of inflammatory bowel diseases have been undertaken with the goal of offering methods of local drug delivery in the lower intestine that reduce both systemic bioavailability and resultant toxicity. In one study, 21 AZA was administered as a delayed-release oral capsule, and effectively showed improved ileocolonic delivery with dramatically reduced systemic bioavailability. In another study, 22 four different formulations of AZA were compared, including preparations suitable for intravenous, oral, delayed-release oral, and rectal foam administration. Taken together, these studies suggest the potential for effective local delivery of AZA in the oral cavity with increased local effect and no or minimal systemic absorption -and hence reduced potential toxicity -with the use of a topical drug formulation.
This case describes oral manifestations that may follow bone marrow transplantation, including oral infections (recurring candidosis and HSV-1 reactivations), hairy leukoplakia-like changes on the tongue, altered taste that improved spontaneously after approximately 4 months following transplant; and findings of progressive systemic sclerosis. [1] [2] [3] 23, 26 Multiple early oral findings following transplant (at approximately day +100) included taste alterations and oral sensitivity with oral ulcerations. The patient continued to have difficulty with oral GVHD with lichenoid and lupus-like and systemic sclerosis-like manifestations. He had no difficulty with mouth dryness. The oral symptoms and signs improved only when systemic prednisone was increased; however, the ulceration of the tongue did not resolve. Various topical applications also had only limited effect. These included topical steroids (dexamethasone rinse, fluocinonide gel, clobetasol ointment), topical cyclosporin A suspension, 4 topical cyclosporin A in a mucoadhesive base (CsA in Zilactin). 5 These approaches have been shown to improve local oral manifestations of GVHD. 4 ,5 A suspension of AZA was begun because of the persisting oral findings. This, however, did not result in a change in systemic dose since the suspension was first introduced as a rinse and then swallowed. Also during these intervals, only minimal changes were made in use of other systemic immunosuppressives, other than at the patient's last admission to hospital due to pneumonia, when AZA suspension was replaced with AZA tablets, and prednisone was increased (10-20 mg/day). During this time, the tongue ulcer worsened despite the increase in prednisone. Topical AZA was prescribed to maintain systemic dosage level following discharge, when reduced doses of prednisone (10 mg/day) were provided. During periods when topical AZA was replaced with AZA by tablet, oral symptoms and signs of GVHD increased, and oral findings improved on several occasions with the resumption of topical application. When seen at last follow-up, the oral ulcerative lesion had improved despite the decreased prednisone dose, and with topical as well as systemic dosing with AZA.
The use of a topical formulation of AZA theoretically offered the benefit of increasing the local therapeutic effect, resulting in improvement in oral symptoms and signs, without increasing the use of systemic immunosuppressive agents. It is possible that the absorption of this agent via oral mucosa may have increased the systemic effect in cases where systemic dosing was not provided, although in this case, the suspension was swallowed in order to maintain the systemic dose previously administered in tablet form. The combination of agents in this case resulted in improved management of previously refractory oral GVHD, without change in systemic drugs and therefore with less risk of increased systemic side-effects.
This case report suggests that topical use of AZA may be an additional means for management of oral immunemediated inflammatory conditions and indicates that the therapeutic potential of this oral topical delivery of AZA should be investigated in patients with oral chronic GVHD, and possibly for other immune-mediated oral mucosal diseases. Potential use of this agent as a topical therapy should continue to be explored.
